Literature DB >> 21672146

Major challenges limiting liver transplantation in the United States.

J A Wertheim1, H Petrowsky, S Saab, J W Kupiec-Weglinski, R W Busuttil.   

Abstract

Liver transplantation is the gold standard of care in patients with end-stage liver disease and those with tumors of hepatic origin in the setting of liver dysfunction. From 1988 to 2009, liver transplantation in the United States grew 3.7-fold from 1713 to 6320 transplants annually. The expansion of liver transplantation is chiefly driven by scientific breakthroughs that have extended patient and graft survival well beyond those expected 50 years ago. The success of liver transplantation is now its primary obstacle, as the pool of donor livers fails to keep pace with the growing number of patients added to the national liver transplant waiting list. This review focuses on three major challenges facing liver transplantation in the United States and discusses new areas of investigation that address each issue: (1) the need for an expanded number of useable donor organs, (2) the need for improved therapies to treat recurrent hepatitis C after transplantation and (3) the need for improved detection, risk stratification based upon tumor biology and molecular inhibitors to combat hepatocellular carcinoma. © 2011 The Authors Journal compilation
© 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 21672146      PMCID: PMC3166424          DOI: 10.1111/j.1600-6143.2011.03587.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  91 in total

1.  Split-liver transplantation in the United States: outcomes of a national survey.

Authors:  John F Renz; Jean C Emond; Hasan Yersiz; Nancy L Ascher; Ronald W Busuttil
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

2.  A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C.

Authors:  S C Rayhill; R Barbeito; D Katz; M Voigt; D Labrecque; P Kirby; R Miller; A Stolpen; Y Wu; W Schmidt
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

3.  The association between hepatitis C infection and survival after orthotopic liver transplantation.

Authors:  Lisa M Forman; James D Lewis; Jesse A Berlin; Harold I Feldman; Michael R Lucey
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

4.  Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.

Authors:  Francesco Paolo Picciotto; Giovanni Tritto; Alfonso Galeota Lanza; Luigi Addario; Massimo De Luca; Giovan Giuseppe Di Costanzo; Filippo Lampasi; Maria Teresa Tartaglione; Giuseppina Marino Marsilia; Fulvio Calise; Oreste Cuomo; Antonio Ascione
Journal:  J Hepatol       Date:  2006-11-27       Impact factor: 25.083

5.  The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.

Authors:  Austin L Spitzer; Oliver B Lao; André A S Dick; Ramasamy Bakthavatsalam; Jeffrey B Halldorson; Matthew M Yeh; Melissa P Upton; Jorge D Reyes; James D Perkins
Journal:  Liver Transpl       Date:  2010-07       Impact factor: 5.799

6.  Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

Authors:  Amandeep K Shergill; Mandana Khalili; Stephanie Straley; Kathy Bollinger; John P Roberts; Nancy A Ascher; Norah A Terrault
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

7.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

8.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

9.  Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

Authors:  Sandrine Faivre; Eric Raymond; Eveline Boucher; Jean Douillard; Ho Y Lim; Jun S Kim; Magaly Zappa; Silvana Lanzalone; Xun Lin; Samuel Deprimo; Charles Harmon; Ana Ruiz-Garcia; Maria J Lechuga; Ann Lii Cheng
Journal:  Lancet Oncol       Date:  2009-07-06       Impact factor: 41.316

10.  Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

Authors:  Michael A Zimmerman; James F Trotter; Michael Wachs; Tom Bak; Jeffrey Campsen; Afshin Skibba; Igal Kam
Journal:  Liver Transpl       Date:  2008-05       Impact factor: 5.799

View more
  60 in total

1.  An ultrasonic caliper device for measuring acoustic nonlinearity.

Authors:  Christopher Hunter; Oleg A Sapozhnikov; Adam D Maxwell; Vera A Khokhlova; Yak-Nam Wang; Brian MacConaghy; Wayne Kreider
Journal:  Phys Procedia       Date:  2016

Review 2.  Proceedings: moving toward cell-based therapies for liver disease.

Authors:  Lisa C Kadyk; Lila R Collins; Neil J Littman; Maria T Millan
Journal:  Stem Cells Transl Med       Date:  2015-01-30       Impact factor: 6.940

3.  Disruption of Type-I IFN pathway ameliorates preservation damage in mouse orthotopic liver transplantation via HO-1 dependent mechanism.

Authors:  X-D Shen; B Ke; H Ji; F Gao; M C S Freitas; W W Chang; C Lee; Y Zhai; R W Busuttil; J W Kupiec-Weglinski
Journal:  Am J Transplant       Date:  2012-03-19       Impact factor: 8.086

4.  Significant lethality following liver resection in A20 heterozygous knockout mice uncovers a key role for A20 in liver regeneration.

Authors:  P Studer; C G da Silva; J M Revuelta Cervantes; A Mele; E Csizmadia; J J Siracuse; S M Damrauer; C R Peterson; D Candinas; D M Stroka; A Ma; M Bhasin; C Ferran
Journal:  Cell Death Differ       Date:  2015-05-15       Impact factor: 15.828

5.  Suramin decreases injury and improves regeneration of ethanol-induced steatotic partial liver grafts.

Authors:  Songqing He; Hasibur Rehman; Yanjun Shi; Yasodha Krishnasamy; John J Lemasters; Rick G Schnellmann; Zhi Zhong
Journal:  J Pharmacol Exp Ther       Date:  2012-11-16       Impact factor: 4.030

Review 6.  Cellular therapy and bioartificial approaches to liver replacement.

Authors:  Jason A Wertheim; Pedro M Baptista; Alejandro Soto-Gutierrez
Journal:  Curr Opin Organ Transplant       Date:  2012-06       Impact factor: 2.640

7.  Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Harrys A Torres; Parag Mahale; Ethan D Miller; Thein H Oo; Catherine Frenette; Ahmed O Kaseb
Journal:  World J Hepatol       Date:  2013-06-27

8.  Ischemic preconditioning attenuates acute lung injury after partial liver transplantation.

Authors:  Qinlong Liu; Hasibur Rehman; Yasodha Krishnasamy; John J Lemasters; Zhi Zhong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-04-20

Review 9.  Ischaemia-reperfusion injury in liver transplantation--from bench to bedside.

Authors:  Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

10.  Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.

Authors:  Ricardo C Gehrau; Valeria R Mas; Catherine I Dumur; Jihee L Suh; Ashish K Sharma; Helen P Cathro; Daniel G Maluf
Journal:  Transplantation       Date:  2015-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.